Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claire Harrison

Showing results (91-100 of 218) with videos related to

Pageof 22
Sort By:
Cortex; a Journal Devoted to the Study of the Nervous System and Behavior|July 27, 2005
Egocentric disorientation following bilateral parietal lobe damageBarbara A Wilson, Emma Berry, Fergus Gracey, et al.
Cancer|February 25, 2023
Early intervention in myelofibrosis and impact on outcomes: A pooled analysis of the COMFORT-I and COMFORT-II studiesSrdan Verstovsek, Jean-Jacques Kiladjian, Alessandro M Vannucchi, et al.
Haematologica|December 17, 2013
Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety studyLuigi Gugliotta, Carlos Besses, Martin Griesshammer, et al.
Leukemia Research|December 4, 2012
Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS studyCarlos Besses, Jean-Jacques Kiladjian, Martin Griesshammer, et al.
The Australian Journal of Rural Health|May 19, 2015
Longlook: initial outcomes of a longitudinal integrated rural clinical placement programScott Kitchener, Renee Day, Daniel Faux, et al.
Future Oncology (London, England)|February 6, 2025
Selinexor plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis: SENTRY Phase 3 study designJohn Mascarenhas, Keri Maher, Raajit Rampal, et al.
Leukemia|July 9, 2024
Myelofibrosis management in routine clinical practice with a focus on patients with cytopenias: recommendations from a global consensus groupSteffen Koschmieder, Prithviraj Bose, Martin H Ellis, et al.
Biorxiv : the Preprint Server for Biology|April 17, 2026
FunctionaL Assigning Sequence Homing (FLASH) maps phenotype to sequence with deep and machine learningDaniel J Cotter, Marie-Claire Harrison, Arjun Rustagi, et al.
BJGP Open|July 30, 2024
Pathways to myeloproliferative neoplasm presentation and time to diagnosis: results from a cross-sectional studyEmma-Louise Tarburn, Lisa Iversen, Charlotte Robertson, et al.
Leukemia & Lymphoma|July 26, 2016
Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyureaGenevieve Douglas, Claire Harrison, Cecily Forsyth, et al.
Pageof 22

Showing results (91-100 of 218) with videos related to

Sort By:
Pageof 22
Cortex; a Journal Devoted to the Study of the Nervous System and Behavior|July 27, 2005
Egocentric disorientation following bilateral parietal lobe damageBarbara A Wilson, Emma Berry, Fergus Gracey, et al.
Cancer|February 25, 2023
Early intervention in myelofibrosis and impact on outcomes: A pooled analysis of the COMFORT-I and COMFORT-II studiesSrdan Verstovsek, Jean-Jacques Kiladjian, Alessandro M Vannucchi, et al.
Haematologica|December 17, 2013
Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety studyLuigi Gugliotta, Carlos Besses, Martin Griesshammer, et al.
Leukemia Research|December 4, 2012
Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS studyCarlos Besses, Jean-Jacques Kiladjian, Martin Griesshammer, et al.
The Australian Journal of Rural Health|May 19, 2015
Longlook: initial outcomes of a longitudinal integrated rural clinical placement programScott Kitchener, Renee Day, Daniel Faux, et al.
Future Oncology (London, England)|February 6, 2025
Selinexor plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis: SENTRY Phase 3 study designJohn Mascarenhas, Keri Maher, Raajit Rampal, et al.
Leukemia|July 9, 2024
Myelofibrosis management in routine clinical practice with a focus on patients with cytopenias: recommendations from a global consensus groupSteffen Koschmieder, Prithviraj Bose, Martin H Ellis, et al.
Biorxiv : the Preprint Server for Biology|April 17, 2026
FunctionaL Assigning Sequence Homing (FLASH) maps phenotype to sequence with deep and machine learningDaniel J Cotter, Marie-Claire Harrison, Arjun Rustagi, et al.
BJGP Open|July 30, 2024
Pathways to myeloproliferative neoplasm presentation and time to diagnosis: results from a cross-sectional studyEmma-Louise Tarburn, Lisa Iversen, Charlotte Robertson, et al.
Leukemia & Lymphoma|July 26, 2016
Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyureaGenevieve Douglas, Claire Harrison, Cecily Forsyth, et al.
Pageof 22